English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The coxibs are nonsteroidal anti-inflammatory drugs (NSAIDs) highly selective for COX-2, an enzyme related to inflammatory processes. At first, their use should present advantages over nonselective NSAIDs, since the inflammatory efficacy would be present but with minimal adverse effects. However, its widespread use showed significant cardiovascular risk and, in treatment over 6 months, predisposition to ulceration, bleeding and stomach pain. The coxibs should be used in patients over 60 years, with a history of peptic ulcer or gastrointestinal bleeding, chronic users of corticosteroids and anticoagulants without concomitant cardiovascular risk. Moreover, they are more expensive and have similar analgesic efficacy to non-selective NSAIDs. In dentistry, the main indications are related to the control of pain and inflammation for a maximum of 3 days or preemptively in oral surgery to control pain and swelling. However, there is no major evidence of the benefits of using these drugs compared to traditional NSAIDs in dentistry.

Inibidores seletivos da cox-2 na odontologia: limitações e efeitos adversos